ADEP 19

ADEP 19 exhibits activity against Mtb H37Rv, with an MIC of 4 μg/mL and an MBC of 4 μg/mL^[1].
ADEP 19 (4-20 μg/mL; 4 days after 14 days of hypoxia) reduces the viability signal of non-replicating hypoxic Mtb H37Rv^[1].
ADEP 19 transiently increases and subsequently decreases intracellular ATP levels in Mtb H37Rv^[1].
ADEP 19 (7 days) in combination with Bedaquiline (HY-14881) produces a strong synergistic antibacterial effect against Mycobacterium tuberculosis (ΣFICI = 0.375); in combination with Rifampicin (HY-B0272), Isoniazid (HY-B0329), and Streptomycin (HY-B1906), no synergistic effect exists^[1].
ADEP 19 (24 hours) exhibits potent antibacterial activity against various Gram-positive bacteria, including Staphylococcus aureus (MIC = 0.125 μg/mL), Enterococcus faecium (MIC < 0.008 μg/mL), Streptococcus pneumoniae (MIC < 0.008 μg/mL)^[1]
ADEP 19 (4-20 μg/mL; 0-14 days) alone completely kills Mtb H37Rv after 14 days and enhances the bactericidal effect of BDQ in time-kill assays^[1].
ADEP 19 (10 μM; 24 h) accumulates intracellularly in Mtb H37Rv, reaching 80% in the cell uptake assay^[1].

ADEP 19 binds/activates Mtb ClpP1P2 with an apparent K_app of 7.5 μM in the peptidase activation assay; it inhibits Mtb ClpC1P1P2 proteolysis with an IC₅₀ of 1.2 μM, and inversely modulates ClpX/ClpC1 ATPase activity in the presence of ClpP1P2^[1].